|
Name |
(1S,3R,3'S,5'R,6S,7R,9E,15R,16S)-15-hydroxy-3,3',15-trimethyl-5'-(2-methylprop-1-enyl)spiro[12-oxatetracyclo[8.5.1.03,7.013,16]hexadec-9-ene-6,2'-oxolane]-11-one
|
Molecular Formula | C25H36O4 | |
IUPAC Name* |
(1S,3R,3'S,5'R,6S,7R,9E,15R,16S)-15-hydroxy-3,3',15-trimethyl-5'-(2-methylprop-1-enyl)spiro[12-oxatetracyclo[8.5.1.03,7.013,16]hexadec-9-ene-6,2'-oxolane]-11-one
|
|
SMILES |
C[C@H]1C[C@@H](O[C@@]12CC[C@]3([C@H]2C/C=C/4\[C@@H]5[C@H](C3)[C@](CC5OC4=O)(C)O)C)C=C(C)C
|
|
InChI |
InChI=1S/C25H36O4/c1-14(2)10-16-11-15(3)25(29-16)9-8-23(4)12-18-21-17(6-7-20(23)25)22(26)28-19(21)13-24(18,5)27/h6,10,15-16,18-21,27H,7-9,11-13H2,1-5H3/b17-6+/t15-,16-,18-,19?,20+,21+,23+,24+,25-/m0/s1
|
|
InChIKey |
JRMCJWMKLHLRLM-GILIFTEFSA-N
|
|
Synonyms |
Ophiobolin A lactone
|
|
CAS | NA | |
PubChem CID | 101916978 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 400.5 | ALogp: | 4.5 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 55.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 29 | QED Weighted: | 0.495 |
Caco-2 Permeability: | -4.77 | MDCK Permeability: | 0.00002410 |
Pgp-inhibitor: | 0.995 | Pgp-substrate: | 0.034 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.086 |
30% Bioavailability (F30%): | 0.701 |
Blood-Brain-Barrier Penetration (BBB): | 0.152 | Plasma Protein Binding (PPB): | 87.46% |
Volume Distribution (VD): | 1.964 | Fu: | 6.57% |
CYP1A2-inhibitor: | 0.042 | CYP1A2-substrate: | 0.323 |
CYP2C19-inhibitor: | 0.176 | CYP2C19-substrate: | 0.825 |
CYP2C9-inhibitor: | 0.123 | CYP2C9-substrate: | 0.048 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.098 |
CYP3A4-inhibitor: | 0.753 | CYP3A4-substrate: | 0.476 |
Clearance (CL): | 11.799 | Half-life (T1/2): | 0.063 |
hERG Blockers: | 0.266 | Human Hepatotoxicity (H-HT): | 0.872 |
Drug-inuced Liver Injury (DILI): | 0.766 | AMES Toxicity: | 0.065 |
Rat Oral Acute Toxicity: | 0.584 | Maximum Recommended Daily Dose: | 0.207 |
Skin Sensitization: | 0.1 | Carcinogencity: | 0.027 |
Eye Corrosion: | 0.023 | Eye Irritation: | 0.068 |
Respiratory Toxicity: | 0.96 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001559 | 0.656 | D0I2SD | 0.287 | ||||
ENC002271 | 0.554 | D04SFH | 0.287 | ||||
ENC005047 | 0.472 | D0Y2YP | 0.262 | ||||
ENC004222 | 0.468 | D06AEO | 0.258 | ||||
ENC005050 | 0.459 | D0P0HT | 0.256 | ||||
ENC002983 | 0.371 | D04GJN | 0.254 | ||||
ENC004490 | 0.328 | D0D2TN | 0.254 | ||||
ENC005882 | 0.326 | D0B4RU | 0.252 | ||||
ENC003783 | 0.322 | D06IIB | 0.252 | ||||
ENC002000 | 0.322 | D0X7XG | 0.252 |